Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Should Spinal MRI Be Routinely Performed in Patients With Clinically Isolated Optic Neuritis?

Meltzer E, Frohman EM, Costello FE, Burton JM, Frohman TC.

J Neuroophthalmol. 2018 Jul 10. doi: 10.1097/WNO.0000000000000685. [Epub ahead of print] No abstract available.

PMID:
30001224
2.

Visual Pathway Measures are Associated with Neuropsychological Function in Multiple Sclerosis.

Nguyen J, Rothman A, Fitzgerald K, Whetstone A, Syc-Mazurek S, Aquino J, Balcer LJ, Frohman EM, Frohman TC, Crainiceanu C, Beier M, Newsome SD, Calabresi PA, Saidha S.

Curr Eye Res. 2018 Jul;43(7):941-948. doi: 10.1080/02713683.2018.1459730. Epub 2018 May 1.

PMID:
29634379
3.

Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon.

Sobhanian MJ, Agarwal R, Meltzer E, Kildebeck E, Frohman BS, Frohman AN, Galetta SL, Saidha S, White O, Villoslada P, Paul F, Petzold A, Rennaker RL, Martinez-Lapiscina EH, Balcer LJ, Kardon R, Frohman EM, Frohman TC.

J Neurol Sci. 2018 Apr 15;387:60-69. doi: 10.1016/j.jns.2018.01.029. Epub 2018 Feb 3.

PMID:
29571874
4.

Preserved canonicality of the BOLD hemodynamic response reflects healthy cognition: Insights into the healthy brain through the window of Multiple Sclerosis.

Turner MP, Hubbard NA, Sivakolundu DK, Himes LM, Hutchison JL, Hart J Jr, Spence JS, Frohman EM, Frohman TC, Okuda DT, Rypma B.

Neuroimage. 2018 Feb 15. pii: S1053-8119(17)31105-9. doi: 10.1016/j.neuroimage.2017.12.081. [Epub ahead of print] Review.

PMID:
29454932
5.

New Ways of "Seeing" the Mechanistic Heterogeneity of Multiple Sclerosis Plaque Pathogenesis.

Meltzer EI, Costello FE, Frohman EM, Frohman TC.

J Neuroophthalmol. 2018 Mar;38(1):91-100. doi: 10.1097/WNO.0000000000000633.

PMID:
29438266
6.

Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis.

Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, Cadavid D, Balcer LJ.

J Neuroophthalmol. 2018 Jan 29. doi: 10.1097/WNO.0000000000000629. [Epub ahead of print]

PMID:
29384802
7.

Visual Fixation Instability in Multiple Sclerosis Measured Using SLO-OCT.

Mallery RM, Poolman P, Thurtell MJ, Full JM, Ledolter J, Kimbrough D, Frohman EM, Frohman TC, Kardon RH.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):196-201. doi: 10.1167/iovs.17-22391.

PMID:
29340646
8.

Analysis of Agreement of Retinal-Layer Thickness Measures Derived from the Segmentation of Horizontal and Vertical Spectralis OCT Macular Scans.

Gonzalez Caldito N, Antony B, He Y, Lang A, Nguyen J, Rothman A, Ogbuokiri E, Avornu A, Balcer L, Frohman E, Frohman TC, Bhargava P, Prince J, Calabresi PA, Saidha S.

Curr Eye Res. 2018 Mar;43(3):415-423. doi: 10.1080/02713683.2017.1406526. Epub 2017 Dec 14.

PMID:
29240464
9.

Characteristics of morphologic macular abnormalities in neuroimmunology practice.

Al-Louzi O, Sotirchos ES, Vidal-Jordana A, Beh SC, Button J, Ying HS, Balcer LJ, Frohman EM, Saidha S, Calabresi PA, Newsome SD.

Mult Scler. 2017 Nov 1:1352458517741206. doi: 10.1177/1352458517741206. [Epub ahead of print]

PMID:
29125422
10.

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL.

Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.

PMID:
28920886
11.

Calibrated imaging reveals altered grey matter metabolism related to white matter microstructure and symptom severity in multiple sclerosis.

Hubbard NA, Turner MP, Ouyang M, Himes L, Thomas BP, Hutchison JL, Faghihahmadabadi S, Davis SL, Strain JF, Spence J, Krawczyk DC, Huang H, Lu H, Hart J Jr, Frohman TC, Frohman EM, Okuda DT, Rypma B.

Hum Brain Mapp. 2017 Nov;38(11):5375-5390. doi: 10.1002/hbm.23727. Epub 2017 Aug 16.

PMID:
28815879
12.

Capturing saccades in multiple sclerosis with a digitized test of rapid number naming.

Hainline C, Rizzo JR, Hudson TE, Dai W, Birkemeier J, Raynowska J, Nolan RC, Hasanaj L, Selesnick I, Frohman TC, Frohman EM, Galetta SL, Balcer LJ, Rucker JC.

J Neurol. 2017 May;264(5):989-998. doi: 10.1007/s00415-017-8484-1. Epub 2017 Apr 7.

13.

Impaired sweating responses to a passive whole body heat stress in individuals with multiple sclerosis.

Allen DR, Huang M, Parupia IM, Dubelko AR, Frohman EM, Davis SL.

J Neurophysiol. 2017 Jul 1;118(1):7-14. doi: 10.1152/jn.00897.2016. Epub 2017 Mar 8.

14.

Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics: A Putative Pathophysiologic Signature for the Retino-Hypothalamic Tract in Multiple Sclerosis.

Meltzer E, Sguigna PV, Subei A, Beh S, Kildebeck E, Conger D, Conger A, Lucero M, Frohman BS, Frohman AN, Saidha S, Galetta S, Calabresi PA, Rennaker R, Frohman TC, Kardon RH, Balcer LJ, Frohman EM.

JAMA Neurol. 2017 May 1;74(5):574-582. doi: 10.1001/jamaneurol.2016.5131.

15.

Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.

Button J, Al-Louzi O, Lang A, Bhargava P, Newsome SD, Frohman T, Balcer LJ, Frohman EM, Prince J, Calabresi PA, Saidha S.

Neurology. 2017 Feb 7;88(6):525-532. doi: 10.1212/WNL.0000000000003582. Epub 2017 Jan 11.

16.

High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.

Beh SC, Kildebeck E, Narayan R, Desena A, Schell D, Rowe ES, Rowe V, Burns D, Whitworth L, Frohman TC, Greenberg B, Frohman EM.

J Neurol Sci. 2017 Jan 15;372:187-195. doi: 10.1016/j.jns.2016.11.012. Epub 2016 Nov 15.

PMID:
28017209
17.

Multiple sclerosis-related white matter microstructural change alters the BOLD hemodynamic response.

Hubbard NA, Turner M, Hutchison JL, Ouyang A, Strain J, Oasay L, Sundaram S, Davis S, Remington G, Brigante R, Huang H, Hart J Jr, Frohman T, Frohman E, Biswal BB, Rypma B.

J Cereb Blood Flow Metab. 2016 Nov;36(11):1872-1884. Epub 2015 Nov 9.

18.

CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics.

Chen D, Ireland SJ, Remington G, Alvarez E, Racke MK, Greenberg B, Frohman EM, Monson NL.

J Immunol. 2016 Dec 1;197(11):4257-4265. Epub 2016 Oct 26.

19.

The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard 'Dick' T. Johnson.

Kildebeck EJ, Narayan R, Nath A, Weiner H, Beh S, Calabresi PA, Steinman L, Major EO, Frohman TC, Frohman EM.

J Neurol. 2017 Apr;264(4):817-828. doi: 10.1007/s00415-016-8293-y. Epub 2016 Oct 12. No abstract available.

PMID:
27734166
20.

Cerebellar Control of Eye Movements.

Beh SC, Frohman TC, Frohman EM.

J Neuroophthalmol. 2017 Mar;37(1):87-98. doi: 10.1097/WNO.0000000000000456. Review.

PMID:
27643747
21.

20/40 or Better Visual Acuity After Optic Neuritis: Not as Good as We Once Thought?

Sabadia SB, Nolan RC, Galetta KM, Narayana KM, Wilson JA, Calabresi PA, Frohman EM, Galetta SL, Balcer LJ.

J Neuroophthalmol. 2016 Dec;36(4):369-376.

PMID:
27472185
22.

Neurotherapeutic Strategies for Multiple Sclerosis.

Frohman TC, Beh SC, Kildebeck EJ, Narayan R, Treadaway K, Frohman EM.

Neurol Clin. 2016 Aug;34(3):483-523. doi: 10.1016/j.ncl.2016.05.001. Review. Erratum in: Neurol Clin. 2016 Nov;34(4):xv.

PMID:
27445239
23.

Characterizing retinal structure injury in African-Americans with multiple sclerosis.

Seraji-Bozorgzad N, Reed S, Bao F, Santiago C, Tselis A, Bernitsas E, Caon C, Frohman E, Bhatti MT, Cree BA, Khan O.

Mult Scler Relat Disord. 2016 May;7:16-20. doi: 10.1016/j.msard.2016.02.009. Epub 2016 Feb 12.

PMID:
27237751
24.

Induction of regulatory T-cells from memory T-cells is perturbed during acute exacerbation of multiple sclerosis.

Mohiuddin IH, Pillai V, Baughman EJ, Greenberg BM, Frohman EM, Crawford MP, Sinha S, Karandikar NJ.

Clin Immunol. 2016 May;166-167:12-8. doi: 10.1016/j.clim.2016.05.001. Epub 2016 May 3.

25.

Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.

Dubey D, Zhang Y, Graves D, DeSena AD, Frohman E, Greenberg B.

Ther Adv Neurol Disord. 2016 May;9(3):211-5. doi: 10.1177/1756285615621029. Epub 2015 Dec 17. Review.

26.

Impaired carotid baroreflex control of arterial blood pressure in multiple sclerosis.

Huang M, Allen DR, Keller DM, Fadel PJ, Frohman EM, Davis SL.

J Neurophysiol. 2016 Jul 1;116(1):81-7. doi: 10.1152/jn.00003.2016. Epub 2016 Apr 13.

27.

In Memoriam: John F. Kurtzke, MD (1926-2015): A Founding Father of Neuroepidemiology and Pioneer of Modern Clinical Trial Design.

Frohman EM, Stüve O, Frohman TC, Lisak R.

JAMA Neurol. 2016 Apr;73(4):482-3. doi: 10.1001/jamaneurol.2016.0030. No abstract available.

PMID:
27064556
28.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.

Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.

PMID:
27011339
29.

Extended interval dosing of natalizumab in multiple sclerosis.

Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885-9. doi: 10.1136/jnnp-2015-312940. Epub 2016 Feb 25.

PMID:
26917698
30.

B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses.

Ireland SJ, Guzman AA, Frohman EM, Monson NL.

J Neuroimmunol. 2016 Feb 15;291:46-53. doi: 10.1016/j.jneuroim.2015.11.022. Epub 2015 Nov 26.

PMID:
26857494
31.

Correlating Function and Imaging Measures of the Medial Longitudinal Fasciculus.

Sakaie K, Takahashi M, Remington G, Wang X, Conger A, Conger D, Dimitrov I, Jones S, Frohman A, Frohman T, Sagiyama K, Togao O, Fox RJ, Frohman E.

PLoS One. 2016 Jan 22;11(1):e0147863. doi: 10.1371/journal.pone.0147863. eCollection 2016.

32.

Acute optic neuritis: a clinical paradigm for evaluation of neuroprotective and restorative strategies?

Qureshi SS, Frohman EM.

Neural Regen Res. 2015 Oct;10(10):1599-601. doi: 10.4103/1673-5374.165286. No abstract available.

33.

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R.

Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29.

PMID:
26621682
34.

A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients.

Ligocki AJ, Rivas JR, Rounds WH, Guzman AA, Li M, Spadaro M, Lahey L, Chen D, Henson PM, Graves D, Greenberg BM, Frohman EM, Ward ES, Robinson W, Meinl E, White CL 3rd, Stowe AM, Monson NL.

ASN Neuro. 2015 Oct 21;7(5). pii: 1759091415609613. doi: 10.1177/1759091415609613. Print 2015 Sep-Oct.

35.

Ocular motor signatures of cognitive dysfunction in multiple sclerosis.

Fielding J, Clough M, Beh S, Millist L, Sears D, Frohman AN, Lizak N, Lim J, Kolbe S, Rennaker RL 2nd, Frohman TC, White OB, Frohman EM.

Nat Rev Neurol. 2015 Nov;11(11):637-45. doi: 10.1038/nrneurol.2015.174. Epub 2015 Sep 15. Review.

PMID:
26369516
36.

Aquatic training in MS: neurotherapeutic impact upon quality of life.

Frohman AN, Okuda DT, Beh S, Treadaway K, Mooi C, Davis SL, Shah A, Frohman TC, Frohman EM.

Ann Clin Transl Neurol. 2015 Aug;2(8):864-72. doi: 10.1002/acn3.220. Epub 2015 Jun 26.

37.

Outer retinal changes following acute optic neuritis.

Al-Louzi OA, Bhargava P, Newsome SD, Balcer LJ, Frohman EM, Crainiceanu C, Calabresi PA, Saidha S.

Mult Scler. 2016 Mar;22(3):362-72. doi: 10.1177/1352458515590646. Epub 2015 Jul 24.

38.

Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosis.

Chahin S, Miller D, Sakai RE, Wilson JA, Frohman T, Markowitz C, Jacobs D, Green A, Calabresi PA, Frohman EM, Galetta SL, Balcer LJ.

Mult Scler Relat Disord. 2015 Jul;4(4):304-10. doi: 10.1016/j.msard.2015.05.005. Epub 2015 May 21.

PMID:
26195047
39.

Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study.

Saidha S, Al-Louzi O, Ratchford JN, Bhargava P, Oh J, Newsome SD, Prince JL, Pham D, Roy S, van Zijl P, Balcer LJ, Frohman EM, Reich DS, Crainiceanu C, Calabresi PA.

Ann Neurol. 2015 Nov;78(5):801-13. doi: 10.1002/ana.24487. Epub 2015 Oct 1.

40.

Asynchrony in executive networks predicts cognitive slowing in multiple sclerosis.

Hubbard NA, Hutchison JL, Turner MP, Sundaram S, Oasay L, Robinson D, Strain J, Weaver T, Davis SL, Remington GM, Huang H, Biswal BB, Hart J, Frohman TC, Frohman EM, Rypma B.

Neuropsychology. 2016 Jan;30(1):75-86. doi: 10.1037/neu0000202. Epub 2015 Jul 6.

PMID:
26146853
41.

Characterization of retinal architecture in Parkinson's disease.

Chorostecki J, Seraji-Bozorgzad N, Shah A, Bao F, Bao G, George E, Gorden V, Caon C, Frohman E, Bhatti MT, Khan O.

J Neurol Sci. 2015 Aug 15;355(1-2):44-8. doi: 10.1016/j.jns.2015.05.007. Epub 2015 May 12.

PMID:
26071887
42.

Ocular motor measures of cognitive dysfunction in multiple sclerosis I: inhibitory control.

Clough M, Millist L, Lizak N, Beh S, Frohman TC, Frohman EM, White OB, Fielding J.

J Neurol. 2015 May;262(5):1130-7. doi: 10.1007/s00415-015-7645-3. Epub 2015 Apr 9.

PMID:
25851743
43.

Ocular motor measures of cognitive dysfunction in multiple sclerosis II: working memory.

Clough M, Mitchell L, Millist L, Lizak N, Beh S, Frohman TC, Frohman EM, White OB, Fielding J.

J Neurol. 2015 May;262(5):1138-47. doi: 10.1007/s00415-015-7644-4. Epub 2015 Apr 9.

PMID:
25851742
44.

Immune-mediated myelopathies.

Greenberg BM, Frohman EM.

Continuum (Minneap Minn). 2015 Feb;21(1 Spinal Cord Disorders):121-31. doi: 10.1212/01.CON.0000461088.63994.a2.

PMID:
25651221
45.

Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis.

Oh J, Sotirchos ES, Saidha S, Whetstone A, Chen M, Newsome SD, Zackowski K, Balcer LJ, Frohman E, Prince J, Diener-West M, Reich DS, Calabresi PA.

Neurology. 2015 Feb 17;84(7):720-8. doi: 10.1212/WNL.0000000000001257. Epub 2015 Jan 21.

46.

Neuro-ophthalmic manifestations of cerebellar disease.

Beh SC, Frohman TC, Frohman EM.

Neurol Clin. 2014 Nov;32(4):1009-80. doi: 10.1016/j.ncl.2014.07.002. Epub 2014 Oct 24. Review.

PMID:
25439294
47.

Retinal damage and vision loss in African American multiple sclerosis patients.

Kimbrough DJ, Sotirchos ES, Wilson JA, Al-Louzi O, Conger A, Conger D, Frohman TC, Saidha S, Green AJ, Frohman EM, Balcer LJ, Calabresi PA.

Ann Neurol. 2015 Feb;77(2):228-36. doi: 10.1002/ana.24308. Epub 2015 Jan 13.

48.

Re-evaluating the treatment of acute optic neuritis.

Bennett JL, Nickerson M, Costello F, Sergott RC, Calkwood JC, Galetta SL, Balcer LJ, Markowitz CE, Vartanian T, Morrow M, Moster ML, Taylor AW, Pace TW, Frohman T, Frohman EM.

J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):799-808. doi: 10.1136/jnnp-2014-308185. Epub 2014 Oct 29. Review.

49.

The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.

Ireland SJ, Guzman AA, O'Brien DE, Hughes S, Greenberg B, Flores A, Graves D, Remington G, Frohman EM, Davis LS, Monson NL.

JAMA Neurol. 2014 Nov;71(11):1421-8. doi: 10.1001/jamaneurol.2014.1472.

50.

Hiding in plain sight: a closer look at posterior cortical atrophy.

Beh SC, Muthusamy B, Calabresi P, Hart J, Zee D, Patel V, Frohman E.

Pract Neurol. 2015 Feb;15(1):5-13. doi: 10.1136/practneurol-2014-000883. Epub 2014 Sep 12. Review.

PMID:
25216669

Supplemental Content

Loading ...
Support Center